In a significant victory for the protection of unborn life, the Fifth Circuit Court of Appeals has temporarily blocked the FDA’s radical 2023 regulation that allowed abortion pills to be dispensed via mail and telemedicine.
The court’s order mandates that mifepristone must once again be obtained in person, effectively halting the Biden administration's attempt to turn the postal service into an abortion clinic.
The ruling specifically highlights the necessity of respecting state-level bans on medical abortions, noting that the FDA’s previous actions undermined Louisiana’s policy recognizing the humanity of the unborn. Louisiana Attorney General Liz Murrill praised the decision, noting that the Biden-era rules had facilitated the deaths of thousands of children.
While pro-abortion activists and officials in states like New York continue to push their extreme agenda, this ruling provides a necessary check on the FDA’s reckless expansion of chemical abortion drugs.
The case, which challenges the safety and regulatory oversight of the two-pill regimen, will continue to move through the courts, offering a chance to hold the federal government accountable for its disregard of state laws and the sanctity of life.
Tags
